Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the ...

It is a change in the retina, the light sensing layer of the ... age of 50 is an increase of flashes in the eyes, or spots or floaters in the vision. Floaters are natural debris that's in the ...

In a meta-analysis, Saw and coworkers compared trials on retina detachment surgery and found no clear evidence in favor for any technique. It seemed that too many aspects are important for the ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

These promoters drive strong and specific gene expression in rod and cone photoreceptors even in mid-to-late stages of disease, outperforming most currently used promoters in retinal gene therapy.

Inherited retinal degenerations (IRDs) are a group of genetic disorders that lead to progressive vision loss as the light-sensing cells of the eye—the photoreceptors—die due to mutations in genes ...

Police say the Northern Rockies detachment building in Fort Nelson, B.C., had to be temporarily evacuated on Thursday after "a considerable amount of smoke" from the fire entered the building ...

Durham-based Atsena Therapeutics has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for ATSN-201, its gene therapy product for the ...

Kelowna, B.C., which hosts the largest RCMP detachment in Canada, is exploring the possibility of ditching the national police force. The city has issued a request for bids, seeking a company to ...

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Lejla Vajzovic, MD, FASRS, shares pearls on delivery of subretinal gene therapy to treat common and ...

He also showed improved shot-creation ability, particularly when coming off on-ball screens for floaters and mid range jump shots. Henshall didn’t do much to stand out at the Combine ...

It is focusing on retinal diseases, with its most advanced programme AGTC-501 for X-linked retinitis pigmentosa (XLRP), which is in the phase 2/3 VISTA trial. AGTC-501 is vying to become the first ...